Haploidentical Stem Cell Transplantation  by Nassar, Amr Ahmed
review
Hematol Oncol Stem Cell Ther 5(2)     Second Quarter 2012 hemoncstem.edmgr.com 73
Bone marrow transplantation, through a variety of cellular, humoral and cytokine pathways, is a potentially curative therapy for different hema-
tologic disorders. Although the majority of allogeneic 
marrow transplantations have been performed using 
either HLA-identical sibling or closely HLA-matched 
(ie, one-antigen–mismatched) family donor, alternative 
donor sources such as unrelated or more highly HLA-
disparate family donors have emerged as alternative op-
tions under certain conditions.1 
The probability of finding HLA-matched sibling 
donors is not high and is always decreasing due to the 
modern trend towards lower family size. The search 
for matched unrelated donors is time consuming, and 
might interfere with the optimum timely management 
of the patients. Again, the utilization of cord blood as 
a source of stem cells suffers from several limitations, 
including the low stem cell content as compared to the 
requirement of an adult patient, late engraftment after 
transplantation and limitations in post-transplant cel-
lular therapy (boost stem cell dose and donor lympho-
cyte infusion).2 
Stem cell transplantation across the major histo-
compatibility complex (MHC) barrier—as in haploi-
dentical SCT-has been tried in the past, with several 
limitations including higher graft failure rate, delayed 
immune reconstitution after transplantation with high 
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the feasibility of stem cell transplantation across the major histocompatibility (mhC) barrier—as in 
haploidentical stem cell transplantation (sCt)—has been proved for some time in several studies. the 
main limitations include a higher graft failure rate, delayed immune reconstitution after transplantation 
with high rates of life-threatening infections, a higher incidence of post-transplant lymphoproliferative 
disease (PtLPD), and severe acute and chronic graft-versus-host disease (GVhD). in an attempt to reduce 
the transplant-related morbidity/mortality, several techniques had been evaluated involving condition-
ing regimen intensity, graft engineering, post-transplant cellular therapy and immunosuppression. this 
review will describe the current situation. it will also discuss initiatives and strategies to overcome the 
limitations associated with transplant across the mhC barrier.
rates of life-threatening infections, a higher incidence of 
post-transplant lymphoproliferative disease (PTLD), 
and severe acute and chronic graft-versus-host disease 
(GVHD).3,4
In this article, we will try to find answers from the 
published literature to the questions that might help to 
further improve the outcome of haploidentical trans-
plantation. These questions are: 
1. What is the best conditioning regimen? 
2. What is the optimum graft composition? 
3. What is the best graft engineering method? 
4.  What is the best GVHD prophylaxis in this par-
ticular setup? 
Conditioning regimen in haploidentical stem cell 
therapy 
Myeloablative vs reduced intensity conditioning 
Both a myeloablative and reduced intensity condition-
ing regimen have been used in haploidentical trans-
plantation. In most of the studies using myeloablative 
conditioning, primary engraftment was obtained in 
the vast majority of patients with a relatively low inci-
dence of GVHD. However, non-relapse mortality was 
relatively higher. Opportunistic infection was the main 
cause of non-relapse mortality (NRM) in most of the 
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studies, reflecting delayed immune reconstitution after 
myeloablative conditioning and vigorous T cell deple-
tion.5-12 
Table 1 shows the data from several clinical trials 
employing different myeloablative conditioning regi-
mens. 
Other reports have evaluated reduced intensity 
conditioning regimen before infusion of haploidentical 
stem cells, based on  the following principles: 
1.  The less transplant-related toxicity and early mor-
tality of this technique, 
2.  The potentially lower incidence of GVHD, 
yet preserving a potent graft versus malignancy 
(GVM) effect following donor lymphocyte infu-
sion (DLI). 
The engraftment rates in these studies were com-
parable to that after a myeloablative regimen. Reduced 
intensity conditioning regimens were not associated 
with lethal viral infection in most reports which could 
be explained by the rapid immune reconstitution, fast 
recovery of thymopoiesis, and by a rapid recovery of the 
T cell receptor repertoire. This is translated into less 
transplant-related mortality. However, there is a higher 
incidence of relapse related mortality.13-19 
Table 2 shows some of the reduced intensity con-
ditioning haploidentical transplant studies and their 
results. 
Anti-thymocyte globulin (ATG)-based conditioning regi-
men 
The advantage of including ATG in conditioning was 
obvious from several studies. First, ATG has a relatively 
prolonged half-life in vivo and can be detected even 30 
days or longer after its administration.20 Thus, it was 
found to potently delete T lymphocytes for a long period 
in vivo, preventing GVHD with no increase in incidence 
of relapse.21 
Second, ATG included in conditioning results in a 
faster donor chimerism after HCT, especially for trans-
plantations from alternative donors.22 
However, the use of ATG in the conditioning regi-
men is not priceless. It can damage hematopoietic stem 
cells and retard immune reconstitution for several 
months after BMT.23 The use of anti-thymocyte globu-
lin (ATG) for ex vivo T-cell depletion was not impres-
sive. In a clinical trial conducted at the Massachusetts 
General Hospital, cyclophosphamide, equine anti-
thymocyte globulin (ATG) for ex vivo T-cell depletion 
and pre-transplant thymic radiation were given before 
haploidentical transplant. Because of a high incidence of 
acute GVHD in the initial cohort of patients, MEDI-
507 (a monoclonal anti-CD2 antibody) was substituted 
Table 1. myeloablative conditioning regimen for haploidentical transplant.
   Centre Disease Patients (n) Conditioning GVHD prophylaxis NRM (%) Survival Reference 
   University of 
   South Carolina aml/all   201
TBi/Vp-16/CY/
ara-C/aTG, CYa
partial TCd, CSa, 
aTG/mp 51
dFS: 18%
OS: 19%
@ 5 years
mehta J,et al 20045
   Japan  
   (multicenter) leukemia, mdS 135 
BU/CY/ara-C/
meCCnU/aTG 22 
64%/71% @ 2 years
CSa/mTX/mmF 22 
dFS: 64%
OS: 71%
@ 2 years
Kato S et al , 20006
   Teubingen 1 Hm, nmd 63 TBi or BU + CY/TT ± FlU TCd pBSC 29
dFS: 48% 
@ 3 years 
(all, nHl in Cr)
lang p et al 20047
   emory  Hm 28 aTG based myeloablative TCd 64 OS: 7%
Walker eK et al, 
20048
    royal marsden  aml/all 35 TBi/CY or TBi/mel CSa±mTX 34 OS: 31% @ 6-36 months
powles rl et al 
19839
   perugia
aml/all
refractory/ Cr1/ 
Cr2
255 TBi-TT- FlU-aTG T cell depletion 41
dFS all: 25% 
dFS aml: 40% @3 
years
aversa F 200810
   Beijing Hm 171
ara C- Bu12- Cy-
aTG- 
me CCnU
CSa, mmF, mTX 22.8 OS: 64.9% @ 2 years
Huang XJ et al 
200611
aml: acute myeloid leukemia, all: acute lymphoblastic leukemia, TBi: total body irradiation, Cy: cyclophosphamide, Vp-16: etoposide, aTG: anti-thymocyte globulin., TCd: T-cell depletion, CSa: cyclosporine a, 
mp: methyl prednisolone, mdS: myelodysplastic syndrome,  BU: busulfan, mTX:  methotrexate, mmF: mycophenolate mofetil,  Hm: hematologic malignancy, nmd: non-malignant disease,  TT: thioptepa., Flu: 
fludarabine, pBSC: peripheral blood stem cell, mel: melphalan, GvHd: graft versus host disease.
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for ATG. After several modifications of the regimen to 
address problems of GVHD and graft rejection, the cur-
rent conditioning regimen includes cyclophosphamide 
and fludarabine, MEDI-507 and thymic radiation.15 
This study points to the fact that although engraftment 
across MHC was feasible using ATG based condition-
ing, GVHD remained a problem and additional mea-
sures should be taken to address this problem. 
Alemtuzumab-based conditioning regimen
Alemtuzumab (Campath-1H) is a humanized mono-
clonal antibody directed against human CD52 that is 
expressed at a high density on B, T cells and dendritic 
cells, but not on hematopoietic stem cells.24 The unique 
pharmacokinetic profile, in which a lympholytic concen-
tration remains for approximately 2 months after trans-
plantation, may contribute to the potent effect against 
GVHD. Depletion of host dendritic cells, which also 
express CD52, could be another mechanism to prevent 
GVHD.25,26 The prophylactic effect of alemtuzumab 
against aGVHD might be much stronger than that of 
ATG.27 
Kanda et al evaluated the safety of unmanipulated 
peripheral blood stem-cell transplantation from mis-
matched unrelated donors using an alemtuzumab-based 
conditioning. All 12 studied patients achieved early 
post-transplant neutrophil engraftment with complete 
donor-type chimerism and a cumulative incidence of 
grades III to IV acute GVHD of only 9%.28 Another 
advantage of alemtuzumab is that it eliminates not only 
T cells but also B cells, and thus there might be a lower 
risk of post-transplant lymphoproliferative disorders. 
However, alemtuzumab-based conditioning is associ-
ated with strong immune suppression and a delayed im-
mune reconstitution after transplantation, which might 
lead to higher incidence of CMV reactivation.29 
Another possible disadvantage of alemtuzumab is 
that it might eliminate NK cells, which might be impor-
tant for a GVM effect.30
Koh et al reported that the lympholytic effect of 
alemtuzumab on NK cells was weaker than that on 
T cells and the use of alemtuzumab for ex vivo T cell 
depletion—alemtuzumab “in the bag”—resulted in the 
99.8% and 94% depletion of CD4+ and CD8+ T cells, 
respectively, whereas 30% of NK cells were conserved in 
the graft.31
Alemtuzumab had been reported to increase the in-
cidence of grade II-IV cardiac complications according 
to the Bearman criteria.32 It might also increase the in-
cidence of relapse after stem cell therapy.33,34 Therefore, 
alemtuzumab might be appropriate for patients with 
low disease burden, whereas it may be better to avoid 
alemtuzumab-based conditioning for patients with ac-
tive and more advanced disease. 
Table 2. reduced intensity conditioning regimen for haploidentical transplant.
   Center Disease Patients (n) Conditioning GVHD prophylaxis NRM (%) Survival Reference 
   Teubingen 2 refractory Hm, Saa 38
Flu, thiotepa, melph, 
and the anti-Cd3
mmF for patients 
who received 
>25 000/kg T cells
2.6
dFS (good risk): 70% 
dFS (bad risk): 20% @ 
2 years
Handgretinger r et al 
200713
   St. Jude 
   Children’s 
   research 
   Hospital
refractory Hm 22 Flu, thiotepa, melph, and the anti-Cd3 TCd pBSC 12
dFS: 36% 
@18 months Chen X et al, 2006
14
   massachusetts 
   General 
   Hospital
leukemia, 
lymphoma 12
CY, anti-Cd2 mab, 
thymic XrT
CSa (‡35 d)±ex vivo 
TCd pBSC 25
dFS: 17%
OS: 25% 
@ 2 years
Spitzer Tr et al, 200315
   Johns Hopkins  leukemia, mdS 13 TBi/CY/FlU post-BmT CY CSa, mmF 8
dFS: 38%
OS: 46% 
@  6 months
O’donnell pV 
et al 200216
   Japan  
   (multicentre) leukemia, nHl 35
myeloablative (n=24)
non-myeloablative 
(n=11)
microchimeric nima 
mismatched donor 
SCT tacrolimus ± 
other drugs
31
dFS: 40%
OS: 43%
 @ 20 months
ichinohe T 
et al 200417
   dukes 
   University Hm, Saa 49
Flu -Cy-Campath
 GCSF mmF±CSa 30.2
OS:  31%for Hm
63 %for Saa
@ 1 year
rizzieri da 
et al, 200718
Hm: hematologic malignancy., Saa: severe aplastic anemia, Flu: fludarabine.,  mel: melphalan., mmF: mycophenolate mofetil., TCd: T-cell depletion.,  GvHd: graft versus host disease, nHl: non Hodgkin’s 
lymphoma,  nima: non-inherted maternal antigens, G-CSF: granulocyte colony stimulating factor,  CSa: cyclosporine a.
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graft processing and composition 
Until the last decade, the wide application of haploi-
dentical transplant was limited by the high incidence of 
GVHD in unmanipulated transplant and graft failure 
in extensive T-cell depleted transplants. However, the 
past decade witnessed great progress in graft engineer-
ing which together with the development of new con-
ditioning protocols has allowed for better outcomes.35 
The outcome of different depletion techniques depends 
on the graft composition that can be achieved by this 
technique. The most important constituents of the graft 
in this respect is expected to be CD34+ cells, T cells, B 
cells and NK cells. 
Graft processing might be done by several techniques. 
Positive and/or negative selections of hematopoietic 
stem cells are the most commonly used. In negative se-
lection, unwanted contaminating cells are eliminated us-
ing monoclonal antibodies, which are specifically direct-
ed against line-specific antigens. Contaminating cells are 
eliminated by means of lysis by complement or through 
physical or immunomagnetic systems.35
Positive selection techniques that are based on 
CD34+ antigen selection are the most commonly 
used when selecting hematopoietic stem cells for clini-
cal use.35 Several systems had been used to process the 
graft using either negative selection, positive selection 
or a combination of both methods. Table 3 summarizes 
these systems. 
CD 34+ dose 
The use of megadose of CD34+ stem cells to induce 
engraftment across MHC barrier was suggested by 
Rachamim et al. They evaluated the effect of purified 
CD34+ cells on primary cultures of cytotoxic T lym-
phocytes. This study showed that CD34+ cells can 
inhibit the development of specific cell-mediated im-
mune responses against their own HLA antigens but 
not against third party. Also, they noticed that this “veto 
effect” requires two conditions: direct contact between 
the effector cells and the CD34+ cells and the optimum 
CD34+/effector ratio should be 0.5-1.40,41 
Although the optimal dose of stem cells in the graft 
varied from one study to another, there is agreement be-
tween different studies that a higher stem cell dose is re-
quired to overcome the MHC barrier.42,43 The Tübingen 
group and others showed that CD34+ cell dose less than 
8×106/kg might not be sufficient to achieve engraftment 
across the MHC barrier,19,44 while the Perugia group ob-
served good engraftment at an average CD34+ cell dose 
of 10×106/kg.45 
However, the CD34+ cell dose sufficient for en-
graftment across the MHC barrier seems to depend on 
several other factors, including the immune suppres-
sive component of the conditioning regimen and the 
presence of other graft facilitating cells in the harvest. 
In a second report from the Tübingen group, they used 
T cell depletion strategy where T and B cells (CD3/
CD19) were negatively depleted in the PBSC harvest. 
They achieved a level of T cell depletion equal to 3.5 to 
4 logs using anti-CD3- and anti-CD19-coated micro-
beads on a CliniMACS device. The collected graft was 
then infused into adult patients following reduced dose 
conditioning. In contrast to the CD34+ positive selec-
tion strategy pioneered by the Perugia group, CD3/
CD19-depleted grafts harvested using this strategy not 
only contain CD34+ stem cells, but also CD34− pro-
genitors, natural killer, dendritic and graft-facilitating 
cells. In this study, the presence of other graft facilitating 
cells allowed better engraftment even with lower average 
CD 34+ cell dose (8.6×106 vs 10×106/kg). This study 
demonstrated the interactive relationship among the 
conditioning regimen, graft composition and transplant 
outcome.46 
t cell 
The level of T cell depletion from the graft that would 
Table 3. Some of the commonly used ex vivo graft manipulation techniques.
   Method Mode of processing Name of the system Reference
   SBa agglutination and 
   e-rosetting negative selection - aversa F et al 1994
36
   e-rosetting + 
   immunoadsorption negative and positive selection Ceprate system aversa F et al 1998
37
   immunomagnetic and anti-
   Cd4/Cd8 and Cd19/Cd22
positive selection and double 
negative isolex 300i system Stainer CJ et al , 1998
38
   immunomagnetic positive selection ClinimaCS system Slaper-Cortenbach iC et al 199939
SBa: soya bean antigen.
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allow engraftment and, early immune reconstitution 
without increased incidence of GVHD, was evalu-
ated in several studies.47-49 A median of 3 to 4 logs T 
cell depletion was not enough to prevent GVHD in a 
matched transplant.47 However, more than 4 logs T cell 
depletion allowed good engraftment with no GVHD in 
the same study and in another 43 patients who under-
went haploidentical transplantation.38 
The Acute Leukemia Working Party (ALWP) of 
the European Blood and Marrow Transplant (EBMT) 
Group conducted a survey of fully haploidentical he-
matopoietic stem cell transplantation in 266 adults 
with high-risk acute leukemia. They reported that an 
ATG-based conditioning regimen followed by ex vivo 
T-cell depleted graft to a mean of 1×104 CD3+cells/
kg (range, 0-6.4) prevented GVHD without any post-
transplant immune suppression.50 
The Perugia group reported the outcome of 255 
acute leukemia patients after haploidentical stem cell 
therapy. The median T cell count was 2×104 cell/kg. 
After a fludarabine-based conditioning regimen, they 
achieved a 95% engraftment rate, which rose to 98% 
after a second haplotransplant with further immuno-
suppression with fludarabine, cyclophosphamide and 
ATG. GVHD was prevented without any post-trans-
plant immunosuppression, confirming that a threshold 
dose of 2×104 CD3+ cell/kg prevents severe GVHD 
as long as it is associated with ATG in the conditioning 
regimen. Disease relapse as well as infectious complica-
tions remained high after such an approach.10 
However, in the Aversa et al study, relapse rates were 
lower than expected in patients who had unfavorable 
prognostic features at transplant, and where 18% and 
30%, respectively, of AML and ALL patients trans-
planted in any CR relapsed. Relapse rate was signifi-
cantly lower after transplantation from NK alloreactive 
donors (3% vs 47%). Also, 41% of patients died of non-
relapse causes. Most deaths were caused by infections, 
the majority of which were CMV and Aspergillus. In 
this study, the cumulative incidence of non-relapse mor-
tality was related to disease stage at transplant and was 
significantly higher in patients who were transplanted 
in relapse (58% vs. 36%).37 However, the ‘megadose’ 
approach, the use of a reduced intensity conditioning 
regimen with less damage to the thymus, rapid preemp-
tive antiviral therapy, especially for adenovirus (ADV), 
and the use of ADV-specific T cell infusion for some 
patients were all shown to reduce the incidence of non-
relapse mortality following haploidentical transplant at 
the Tübingen study.19 
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78 Table 5. different approaches for GVHd prophylaxis in haploidentical SCT.
   Center Patients (n) Conditioning GVHD prophylaxis NRM (%) aGVHD cGVHD Survival Reference 
immune 
suppressant aTG ex vivo TCd
   University of 
   South Carolina 201
myeloablative 
conditioning CSa, mp Yes partial TCd, 51 13% 15%
dFS: 18%
OS: 19%
@ 5 years
mehta J et al 
20045
   Japan  
   (multicentre) 135 CSa/mTX/mmF Yes
no 22 40% 55%
dFS: 64%
OS: 71%
@ 2 years
lu dp 
et al 200672
   Teubingen 63 no no Yes 29 7% 13%
dFS: 48% 
@ 3 years 
(all, nHl in Cr
lang p 
et al 20047 
   emory  28 - Yes Yes 64 nS nS OS: 7% Waller eK et al 20048
   royal marsden 164 CSa ± mTX - no 51%      nS      nS OS: 31% @ 6-36 months
Singhal S 
et al 200373
   perugia 255 T cell depletion Yes Yes 41 - -
dFS all: 25% 
dFS aml: 40% 
@3 years
aversal F 200810
   Beijing 171 CSa, mmF, mTX Yes no 22.8 55% 46.9% OS: 64.9% @ 2 years
Huang XJ 
et al 200611
   Tübingen 2 28 riC+OKT-3 - no Yes 39% @ 2 years 54% 18% OS 31% @ 2 years
Federmann B 
et al l 201146
   St. Jude 
   Children’s 
   research  
   Hospital
22
riC=22 
myeloa-
blative= 12
mmF± CSa no Yes - 36% 22% 25% @ 2 years Chen X et al 200614
   massachusetts 
   General 
   Hospital
12 riC+ anti Cd2 CSa no Yes=4no=8 na - - -
Spitzer Tr 
et al 200315
   Japan 
   multicentre 
   study
35
myeloa-
blative=24
riC=11
Tacrolimus ± 
methotrexate ± 
steroids
± mmF 
no no 11\35 56% 83% OS=43%dFS=40%
ichinohe T 
et al 200417
   dukes 
   University 49
riC+ campath- 
H1 mmF±CSa no no 15\49 16% 14%
dFSS=31%
OS=43%
@ 1 year
rizzieri da 
et al 200718  
SCT: stem cell transplant, GvHd: graft versus host disease, aTG: anti-thymocyte globulin., nrm: non relapse mortality, CSa: cyclosporine a., mp: methyl prednisolone., TCd: T-cell depletion., mmF: mycophenolate mofetil., mTX:  methotrexate.,  aml: acute 
myeloid leukemia. , all: acute lymphoblastic leukemia., non-hodgin’s lymphoma., riC: reduced intensity conditioning
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Extensive T-cell depletion without comparable B-cell 
depletion was associated with a significant increase in 
the incidence of Epstein Barr virus-induced lmphopro-
liferative disorder (EBV-LPD), especially with the use 
of ex vivo graft engineering.51-54 Also T-cell depletion 
together with use of ATG and a high CD34+ cell count 
in the graft were the most important factors influencing 
post-transplant EBV reactivation.55,56 
Several investigators had suggested that the ratio of 
T and B cells in the graft is important for EBV sur-
veillance. Meijer et al suggested that a T/B cell ratio of 
2.5 is sufficient to prevent EBV-LPD.51 However, the 
optimal T/B cell ratio is currently not known and is de-
pendent on several factors, such as use and dosage of 
ATG.51,57 
Cavazzana et al showed that none of the patients 
who had received transplants from a partially matched-
related donor (PMRD) developed EBV-LPD when ex 
vivo T and B cell depletion was performed, whereas 7 of 
19 historical controls developed EBV-LPD when only 
T cell depletion was carried out.58 In this study, fewer 
than a median of 0-5×106 B cells were infused to re-
cipients. This data was confirmed in the study of Aversa 
et al, where B-cell depletion was 2.3 logs and the in-
fused B-cell dose was 4.09-2.53×105/kg. The incidence 
of EBV-related lymphoproliferative disorders was less 
than 3 %.45 
nK cell 
After extensive T cell depletion, the NK cell becomes 
the main effecter cell in the graft versus leukemia (GVL) 
reaction. HLA class I disparities driving NK cell allo-
reactions in the GVH direction mediate strong GVL 
effects, produce higher engraftment rates and do not 
cause GVHD. NK cell alloreactivity may be a unique 
therapeutic tool for tolerance induction and clear-
ance of leukemia in hematopoietic transplantation.59-61 
Bachanova et al reported that IL-2 activated autologous 
NK cells can induce, but not maintain durable remis-
sions in lymphoma patients.62 
The relationship between the graft content of NK 
cells and the effectiveness and safety of haploidentical 
transplantation was not adequately studied. However, 
in a multivariate analysis by the Korean study of 61 
myeloabative conditioning allo-PBSCT from matched 
sibling, there was strong correlation between higher 
dose of  NK cells (≥5×107/kg) and a lower incidence 
of non-relapse mortality (NRM), GVHD and infec-
tious events.61 
In the Tübingen study, the graft contained an aver-
age of 137×106/kg CD56+ NK cells (range 9–550). 
The rate of engraftment was 83%. Acute GVHD grades 
2-4 were seen in 27% of patients. GVHD prophylaxis 
consisted of CD3 depletion and post-transplant myco-
phenolate mofetil starting from day 1 in those patients 
who received greater than 25 000/kg T cells with the 
graft. NRM of 2.6% with EFS of 70% for the good risk 
group and 20% for the relapsed/refractory group were 
observed.19 
Rather than the dose of NK cells in the graft, the 
speed of NK cell recovery looks to be more important 
in this regard. Early NK cell recovery as occurring in the 
setup of reduced intensity conditioning would be expect-
ed to have positive effect on GVL reaction, antiviral im-
munity and suppression of the GVHD.18,19,46,63-65 
The data from these studies suggest that the higher 
graft content of alloreactive NK cells would be expected 
to ablate leukemic cells and recipient T cells, permit-
ting the use of reduced intensity conditioning regimen. 
Also, it can ablate the recipient dendritic cells (DCs) 
which trigger GVHD, thus protecting from GVHD 
while permitting a higher T cell content in the graft. 
In other words, the graft composition and the relative 
content of each of the cellular components in the graft 
have direct implication on the outcome of haploidenti-
cal SCT. Table 4 shows different graft composition in 
different studies and its relation to the outcome. 
haploidentical stem cell therapy and gVhD 
Being a major problem in haploidentical SCT, GVHD 
prophylaxis has attracted the attention of several study 
groups. Some of these studies used immunosuppressive 
agents while others depended on variable degrees of T 
cell depletion or a combination of both. In spite of that, 
30% to 70% of haplotransplant recipients suffer from 
GVHD.2,66,67,68 
The Italian studies focused on myeloabaltive condi-
tioning followed by infusion of a megadose of CD34+ 
cells with extensive T-cell depletion and no post-
transplant immunosuppressive agents. Although they 
reported a lower incidence of GVHD, the procedure 
was associated with significant TRM of 35 to 40 %, 
mainly due to delayed immune recovery and infec-
tions.12,35,37,45,69
The German group tried to overcome this problem 
by reducing the intensity of conditioning and targeting 
a higher dose of more than 10×106 CD34+ cells/kg 
body weight with extensive T-cell depletion. Although 
engraftment was rapid at a median 15 days, T- and B-cell 
reconstitution was delayed, whereas NK cell reconstitu-
tion occured early and fast. aGVHD occurred in 54% 
of patients, while 18% developed cGVHD.13,19,44,46 
Cellular therapy, which theoretically not only reduc-
es GVHD, but also augments the graft-versus-leuke-
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mia (GVL) effect, had been studied in this field. An ex-
ample of this cellular therapy is infusion of alloreactive 
NK.62,69  Pre- and post-transplant infusion of alloreac-
tive NK cells either in preparation for the coming graft 
or similar to donor lymphocyte infusion for relapsed 
cases has been suggested to have the same positive effect 
on engraftment and graft versus host disease.61,62,69,70 
De Angelis et al assessed the role of different NK 
subsets in exerting GVL effects in recipients of hap-
loidentical transplants. They reported that CD3–/
CD56– cells expressed NK cell-associated molecules, 
such as CD16, NKp46, NKp30, CD244 (2B4), 
CD161, and killer cell immunoglobulin-like recep-
tors. CD3–/CD56– cells further exhibited the classi-
cal functional characteristics of NK cells: cytolysis of 
target cells lacking HLA class I, antibody-dependent 
cellular cytotoxicity and cytokine production. These 
results demonstrate that CD56– NK cells are func-
tional, recognize missing self and, like their CD56+ 
counterparts, may contribute to GVL reactions.69 
Bachanova et al also reported the beneficial effect of 
the CD56- subset as anti-tumor cells without increas-
ing GVHD incidence.62 However, further studies are 
needed to completely establish the technique of donor 
NK cell collection and infusion. 
Another example of cellular therapy is coinfusion 
of mesenchymal stromal cells (MSCs). MSCs were 
suggested to have the ability to enhance engraftment 
and reduce GVHD through preventing T-cell activa-
tion and proliferation.71 Liu et al reported in an open-
label, randomized phase 2 clinical study to assess the 
outcome of MSC coinfusion during haploidentical he-
matopoietic stem cell transplantation in a total of 55 
patients. No immediate or long-term toxic side effects 
related to MSC infusion were noted. It also helped 
early engraftment and platelet recovery. There was 
a trend towards a lower incidence of cGVHD, but a 
higher incidence of aGVHD in the group who received 
(MSCs).71  Table 5 shows the outcome of some of the 
approaches to reduce GVHD in haploidentical SCT. 
In conclusion, although haploidentical stem cell 
transplantation is a technically challenging procedure, 
it carries a high risk of complications and transplant-
related morbidity and mortality, yet it remains an op-
tion for those who require SCT, but lack a suitable 
HLA-matched graft either from a related or unrelated 
donor. The level of immunosuppression that is required 
to induce engraftment across MHC is feasible whether 
through conditioning regimen, graft engineering or 
both. Post-transplant complications, mainly GVHD, 
delayed engraftment and infectious complications re-
main considerations. Ongoing research, especially the 
use of adoptive immunotherapy, chemoprophylaxis 
against relevant infectious agents and better graft en-
gineering techniques, might bring haploidentical stem 
cell therapy more into regular practice. 
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